Wells Fargo’s TransCode Therapeutics RNAZ Stock Holding History

Wells Fargo’s Portfolio RNAZ Stock Details RNAZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$342	Hold	55	–	–	﹤0.01%	6548
2026 Q1	$474	Buy	+55	New	+$513	﹤0.01%	6400
2024 Q2	–	Hold	0	–	-$3	–	7368
2024 Q1	–	Hold	0	–	–	–	7437
2023 Q4	–	Hold	0	–	–	–	7127
2023 Q3	–	Hold	0	–	–	–	7465
2023 Q2	–	Hold	0	–	–	–	7466
2023 Q1	–	Hold	0	–	–	–	7411
2022 Q4	–	Hold	0	–	–	–	7126
2022 Q3	–	Hold	0	–	–	–	7242
2022 Q2	–	Hold	0	–	–	–	7367
2022 Q1	–	Hold	0	–	–	–	7683
2021 Q4	–	Hold	0	–	–	–	7704
2021 Q3	–	Hold	0	–	–	–	7416

Other funds holding RNAZ

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Wells Fargo's RNAZ Position: Q2 2026 in Review

Wells Fargo held its TransCode Therapeutics (RNAZ) position steady in Q2 2026 at 55 shares worth $342. The position accounts for ﹤0.01% of the portfolio, ranked #6548.

Wells Fargo first reported a position in RNAZ in Q1 2026 and has held it in 2 quarters since. The position peaked at $474 in Q1 2026. 8 funds tracked by Wall St. Rank hold RNAZ as of Q2 2026.

Wells Fargo held 55 shares of TransCode Therapeutics worth $342 as of Q2 2026.
Wells Fargo left its TransCode Therapeutics share count unchanged in Q2 2026.
TransCode Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6548 holding.
Wells Fargo first reported a position in TransCode Therapeutics in Q1 2026 and has held it in 2 quarters since.
Wells Fargo's TransCode Therapeutics position peaked at $474 in Q1 2026.
8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.